Merck Prostate Cancer 365 - Clinical Trial
What is the Purpose of this Study?
We are doing this study to test the safety and how well these drugs work together in patients with metastatic castrate resistant prostate cancer.
Advanced Prostate Cancer
Who Can Participate in the Study?
Adult patients with advanced prostate cancer that has spread beyond the prostate and has gotten worse after treatment with hormones (ADT).
What is Involved?
If you choose to join this study, you will:
- Complete a screening phase, that will include providing a tumor tissue sample, a physical exam, a blood draw, urine collection, an ECG, and imaging scans
Once you have completed the screening phase, you will:
- Get the study drug Pembrolizumab every 3 weeks through an IV, while taking standard-of-care abiraterone with prednisone by mouth daily
- Return to the clinic every 3 weeks for study visits that will include a physical exam, questions about medications and side effects, study drug infusions, and blood and urine tests
- Have Imaging scans that will be done every 9 weeks for the first year on the study then every 12 weeks
After you finish all the study visits and have finished the study treatment, you will be contacted every 6 months to see how you are doing and to see what other cancer therapies you may be on.